



ZUVENTUS HEALTHCARE LIMITED

CIN: U85320PN2002PLC018324

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C.,

Hinjawadi, Pune - 411057, Maharashtra, India

Tel: +91 20 – 35070033/ 35070000, Fax: +91 20 3507 0060

NOTICE

NOTICE IS HEREBY GIVEN THAT AN EXTRA-ORDINARY GENERAL MEETING (“EGM”) (NO. 02/2025-26) OF THE MEMBERS OF ZUVENTUS HEALTHCARE LIMITED (“THE COMPANY”) WILL BE HELD ON **TUESDAY, MARCH 10, 2026** AT 10.30 A.M. (IST) AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT PLOT NO. P-1 & P-2, IT-BT PARK, PHASE -II, M.I.D.C., HINJAWADI, PUNE – 411 057, MAHARASHTRA, TO TRANSACT THE FOLLOWING BUSINESS:

SPECIAL BUSINESS:

1. **RE-APPOINTMENT OF DR. SHAILESH AYYANGAR (DIN: 00268076) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:**

To consider and, if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) read with the Rules made thereunder (including any statutory modifications or re-enactments thereof for the time being in force), as recommended by the Nomination and Remuneration Committee (“NRC”) and the Board of Directors of the Company, Dr. Shailesh Ayyangar

(DIN: 00268076 and IDDB Registration Number :IDDB-DI-202007-029759), who was appointed as an Independent Director of the Company for a term of 3 (three) consecutive years at the Annual General Meeting of the Company held on July 10, 2023 with effect from May 30, 2023 and holds office upto May 29, 2026, is eligible for re-appointment as an Independent Director of the Company and who has submitted a declaration that he meets the criteria of independence pursuant to the provisions of the Act and in respect of whom the Company has received a notice in writing from a Member under Section 160(1) of the Act proposing his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term of 5 (five) consecutive years with effect from May 30, 2026.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197 and other applicable provisions of the Act read with the Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), Dr. Ayyangar shall be paid such fees, remuneration and/ or profit related commission as the Board / NRC may approve from time to time and subject to such limits, prescribed or as may be prescribed.

RESOLVED FURTHER THAT any Director or Key Managerial Personnel of the Company, be and is hereby severally authorised to do all acts including filing forms with Registrar of Companies and to take all such steps as may be necessary, proper or expedient for the purpose of giving effect to this resolution.”

2. **APPOINTMENT OF MR. SALIL KUMAR PANDEY (DIN: 11521644) AS A DIRECTOR OF THE COMPANY:**

To consider and, if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) read with the Rules made thereunder (*including any statutory modification(s) or re-enactment thereof for the time being in force*), as recommended by the Nomination and Remuneration Committee and the Board of Directors of the Company, Mr. Salil Kumar Pandey (DIN: 11521644), who was appointed as an Additional Director (Executive) of the Company with effect from February 03, 2026, by the Board of Directors of the Company and who holds office up to the date of next annual general meeting, pursuant to the provisions of Section 161 of the Act and in respect of whom the Company has received a notice in writing from Member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company, be and is hereby appointed as a Director (Executive) of the Company, liable to retire by rotation.

RESOLVED FURTHER THAT any Director or Key Managerial Personnel of the Company, be and is hereby severally authorised to do all acts including filing forms with Registrar of Companies and to take all such steps as may be necessary, proper or expedient for the purpose of giving effect to this resolution.”

3. **APPOINTMENT OF MR. SALIL KUMAR PANDEY (DIN: 11521644) AS A WHOLE-TIME DIRECTOR OF THE COMPANY:**

To consider and, if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 198, 203, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) read with the Rules made thereunder (*including any statutory modification(s) or re-enactment thereof for the time being in force*), as recommended by the Nomination and Remuneration Committee and the Board of Directors of the Company, approval of the Members be and is hereby accorded for appointment of Mr. Salil Kumar Pandey (DIN: 11521644) as a Whole-time Director of the Company for a term of 3 (three) consecutive years with effect from February 03, 2026, on the following terms and conditions:

- i) Salary: Not exceeding Rs. 2,19,90,000/- per annum
- ii) Perquisites: Not exceeding Rs. 21,60,000/- per annum
- iii) Bonus: Not exceeding Rs. 59,84,000/- per annum

RESOLVED FURTHER THAT subject to the applicable provisions of Section 197 read with Schedule V of the Act, the approval of the Members be and is hereby accorded for the payment of remuneration within the aforementioned maximum limits, in the event the Company has no profits/inadequate profits in any financial year, which may be in excess of the individual or overall limits prescribed under the Act, and the Rules made thereunder & other applicable laws/ regulations, as amended from time to time and that the Board, be and is hereby authorized to alter or vary the terms of remuneration within the aforementioned limits in compliance with the provisions of the Act.

RESOLVED FURTHER THAT the Board be and is hereby authorized to execute all such agreements, documents, instruments and writings, file requisite filings, settle all questions, difficulties or doubts that may arise in this regard including obtaining of necessary approvals in relation thereto, and to take all such steps as may be necessary, proper or expedient for the purpose of giving effect to this resolution.”

For and on behalf of the Board of Directors
Zuventus Healthcare Limited

Sd/-
Ankita Saraogi
Company Secretary
Membership No. A49275

Place: Pune

Date: February 04, 2026

Registered Office:

Plot No. P-1 & P-2, IT- BT Park,
Phase II, M.I.D.C, Hinjawadi,
Pune – 411 057, Maharashtra

NOTES:

1. The statement pursuant to Section 102 of the Companies Act, 2013 (“the Act”) in respect of the Special Business to be transacted at the Extra-Ordinary General Meeting (“EGM”) is annexed hereto.

2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE EGM IS ENTITLED TO APPOINT A PROXY, TO ATTEND AND VOTE INSTEAD OF HIMSELF/ HERSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY. PROXIES, IN ORDER TO BE EFFECTIVE SHALL BE DULY STAMPED, SIGNED AND FILLED (COMPLETED IN ALL ASPECTS) AND DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE EGM.**

A PERSON CAN ACT AS A PROXY ON BEHALF OF MEMBERS UP TO AND NOT EXCEEDING FIFTY (50) AND HOLDING IN AGGREGATE NOT MORE THAN TEN PERCENT (10%) OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS A PROXY FOR ANY OTHER PERSON OR MEMBER.

3. Members/Proxies should bring the enclosed attendance slip duly filled in, for attending the EGM.

4. Corporate Members intending to send their authorized representatives to attend the EGM are requested to send a certified copy of their board resolution or any other document validly executed by its director or other authorized signatories/persons, authorizing their representative to attend and vote on their behalf at the EGM.
5. Members who hold shares in dematerialized form are requested to bring their Client ID and DP ID for easier identification of attendance at the meeting. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the EGM
6. All documents referred to in the Notice calling the EGM and the Explanatory Statement are available with the Company for inspection by the Members upto the date of this meeting and will also be available at the venue of the EGM.
7. During the period beginning 48 hours before the time fixed for the commencement of the meeting and ending with the conclusion of the meeting, a member would be entitled to inspect the proxies lodged at any time during business hours of the Company, provided that not less than three days of notice is given in writing to the Company.
8. Route map showing directions to reach the venue of EGM is annexed.
9. Members holding shares in the dematerialized (electronic) form may update changes in their address or bank mandate with their respective Depository Participants. The Company or its Registrars cannot act on any request received directly from the shareholders holding shares in electronic form for any change of bank particulars or bank mandates. Such changes are to be advised only to the Depository Participant of the shareholders.
10. Members who have not registered their e-mail addresses are requested to register the same with MUFG Intime India Pvt. Ltd., the Registrar and Transfer Agent of the Company or with the respective Depository Participant(s) for sending future communication(s) in electronic form.

**STATEMENT PURSUANT TO SECTION 102 OF
THE COMPANIES ACT, 2013**

Item No. 1

**Re-appointment of Dr. Shailesh Ayyangar (Din:
00268076) as an Independent Director of the
Company:**

The Members of the Company at their Annual General Meeting held on July 10, 2023, had appointed Dr. Shailesh Ayyangar as an Independent Director of the Company for a term of 3 (three) consecutive years with effect from May 30, 2023 upto May 29, 2026. Pursuant to the provisions of the Companies Act, 2013 (“the Act”), Dr. Shailesh Ayyangar is eligible to be re-appointed as an Independent Director for another term.

In accordance with Section 149(10) and (11) of the Act, an independent director shall hold office for a term upto five consecutive years on the Board of a Company, but shall be eligible for re-appointment on passing of special resolution by the Company.

Brief Profile of Dr. Shailesh Ayyangar:

Dr. Shailesh Ayyangar is an Independent Director of the Company. He was previously associated with Sanofi India Limited as its Managing Director and later as a Non-Executive Director and with Sanofi Synthelabo (India) Private Limited as its Managing Director and Head of Strategic Projects.

Dr. Ayyangar holds a Bachelor’s degree in veterinary science and animal husbandry from the Faculty of Veterinary Science and Animal Husbandry (Gujarat Agricultural University) and a post graduate diploma in Management from Indian Institute of Management, Ahmedabad.

Considering the aforementioned experience and his valuable contribution, in pursuance to the provisions of the Act, based on the recommendation of Nomination and Remuneration Committee and on the performance evaluation, the Board of Directors at its meeting held on February 03, 2026, has approved the re-appointment of Dr. Shailesh Ayyangar as an Independent Director for second term of 5 (five) consecutive years with effect from May 30, 2026, subject to approval of Members of the Company.

Further in the opinion of the Board, Dr. Ayyangar continues to possess the identified core skills, expertise and competencies fundamental for effective functioning in his role as an Independent Director of the Company and his continued association would be of immense benefit to the Company.

The Company has received a notice in writing under the provisions of Section 160 of the Act, from a Member proposing the candidature of Dr. Ayyangar for the office of an Independent Director of the Company. He has conveyed his consent to act as an Independent Director of the Company for second term of 5 (five) years. He has also submitted a declaration to the Board that he continues to meet the criteria of independence as provided in the Act read with the Rules made thereunder. Dr. Ayyangar is not disqualified from being appointed as a Director in terms of Section 164 of the Act.

Furthermore, in the opinion of the Board, Dr. Ayyangar fulfills the conditions as specified in the Act read with Rules made thereunder and Dr. Ayyangar is independent of the management.

A copy of the draft letter of appointment as an Independent Director stating the terms and

conditions, is available for inspection by the Members of the Company.

During his tenure as an Independent Director, he shall be eligible to receive sitting fees and commission as per the provisions of the Act and the Remuneration Policy of the Company.

Except Dr. Shailesh Ayyangar and his relatives, none of the other Directors, Key Managerial Personnel and their respective relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out in Item No. 1.

The Board recommends passing of the Special Resolution as set out in Item No. 1 of the Notice for the approval of Members.

Item Nos. 2 & 3

Appointment of Mr. Salil Kumar Pandey (DIN: 11521644) as a Director of the Company:

Appointment of Mr. Salil Kumar Pandey (Din: 11521644) as a Whole-time Director of the Company:

In order to strengthen the existing Board of the Company, based on the recommendation of the Nomination and Remuneration Committee ("NRC"), the Board of Directors at its meeting held on February 03, 2026, had approved the appointment of Mr. Salil Kumar Pandey (DIN: 11521644) as an Additional Director (Executive) on the Board of the Company, with effect from February 03, 2026, who shall hold office upto the date of the next annual general meeting, in pursuance to the provisions of Section 161(1) of the Companies Act, 2013 ("the Act").

Based on the recommendation of the NRC, the Board of Directors had also approved the

appointment of Mr. Pandey as a Whole-time Director of the Company, for a term of 3 (three) consecutive years with effect from February 03, 2026, subject to approval of Members of the Company, and for payment of remuneration as specified in the resolution, in pursuance to the provisions of Sections 196, 197, 203, and other applicable provisions, if any, of the Act read with the Rules made thereunder and Schedule V of the Act.

Brief profile of Mr. Salil Kumar Pandey:

Mr. Salil Kumar Pandey is currently the Chief Commercial Officer of the Company, responsible for leading Company's commercial strategy and strengthening its sales and marketing effectiveness across India.

Mr. Pandey brings with him over three decades of experience in the Indian pharmaceutical sector and has built a strong understanding of diverse markets and therapeutic segments. Over the course of his career, he has held senior leadership roles across sales and marketing functions, managing large, multi-specialty portfolios and working closely with cross-functional teams to drive sustained business growth and gain market share.

Mr. Pandey holds Bachelor of Science (Physiology) from University of Calcutta. He has also completed Senior Management Development Program from SP Jain Institute of Management & Research, McKinsey Management Program and Executive Development Program from Indian Institute of Management, Ahmedabad.

Pursuant to the provisions of Section 152 of the Act, the directors shall be appointed by the Members through ordinary resolution in the

general meeting of the Company. In view of the same, an approval of the Members is being sought for appointment of Mr. Salil Kumar Pandey as a Director (Executive) of the Company, in this Extra-Ordinary General Meeting. The Company had also received a notice under Section 160 of the Act from a Member, proposing his candidature for the office of director.

Further, considering the aforementioned experience, in pursuance to the provisions of Sections 196, 197 and 203 of the Act, read with Rules made thereunder and Schedule V of the Act, approval of the Members by way of Special Resolution is being sought for appointment of Mr. Pandey as a Whole-time Director on the Board of the Company for term of three (3) consecutive years with effect from February 03, 2026 and for payment of remuneration as specified in the resolution. Mr. Pandey would be liable to retire by rotation.

Mr. Pandey is not disqualified from being appointed as a Director in terms of Section 164 of the Act.

During his tenure and pursuant to contract of service containing terms of his appointment, Mr. Pandey shall devote sufficient time in discharging his duties to the Company diligently and to the best of his abilities and shall comply with the policies and procedures of the Company.

The Board or any Committee thereof shall, in accordance with the statutory limits / approval as may be applicable for time being in force, may revise/ alter/ modify/ amend the terms and conditions of his remuneration from time to time, as they may deem fit.

The Company is involved in the business of dealing in all types, descriptions, specifications, strengths and application of pharmaceutical medicaments in healthcare. The Company has been earning adequate profits. However, as a prudent measure, approval of Members is being sought by way of a Special Resolution for the payment of remuneration to Mr. Pandey, which shall also be the maximum remuneration payable to him, in any Financial Year, during his tenure of appointment, in the event the Company has no profits/inadequate profits, in pursuance to the provisions of the Act.

Mr. Pandey, as on date, does not hold any Equity Shares in the Company.

Except Mr. Salil Kumar Pandey and his relatives, none of the other Directors, Key Managerial Personnel and their relatives are, in any way, concerned or interested, financially or otherwise, in the resolutions set out in Item Nos. 2 & 3.

The Board recommends passing of the Ordinary and Special Resolutions as set out in Item Nos. 2 & 3 of the Notice, respectively, for the approval of the Members.

**For and on behalf of the Board of Directors
Zuventus Healthcare Limited**

**Sd/-
Ankita Saraogi
Company Secretary
Membership No. A49275**

Place: Pune

Date: February 04, 2026

Registered Office:

Plot No. P-1 & P-2, IT- BT Park,
Phase II, M.I.D.C, Hinjawadi,
Pune – 411 057, Maharashtra


DETAILS OF DIRECTOR UNDER SECRETARIAL STANDARD-2 SEEKING APPOINTMENT/ RE-APPOINTMENT AT THE FORTHCOMING EXTRA-ORDINARY GENERAL MEETING FOR ITEM NOS. 1 TO 3:

Name of the Director	Dr. Shailesh Ayyangar	Mr. Salil Kumar Pandey
Age (Yrs.)	71 years	63 years
Nationality	British	Indian
Date of first appointment on the Board	July 27, 2021 <i>(As a Non-Executive & Non-Independent Director)</i> May 30, 2023 <i>(As an Independent Director)</i>	February 03, 2026
Relationship with other Directors and Key Managerial Personnel of the Company	None	None
Area of Expertise	Leadership, Strategy and Industry Expertise	Sales and Marketing, Strategy and Industry Expertise
Qualifications	Bachelor's degree in veterinary science and animal husbandry from the Faculty of Veterinary Science and Animal Husbandry (Gujarat Agricultural University) and a post graduate diploma in Management from Indian Institute of Management, Ahmedabad	Bachelor of Science (Physiology) from University of Calcutta. He has also completed Senior Management Development Program from SP Jain Institute of Management & Research, McKinsey Management Program and Executive Development Program from Indian Institute of Management, Ahmedabad.
Experience/ Brief Resume	Dr. Ayyangar was previously associated with Sanofi India Limited as its Managing Director and later as a Non-Executive Director and with Sanofi Synthelabo (India) Private Limited as its Managing Director and Head of Strategic Projects.	Mr. Salil Kumar Pandey is currently the Chief Commercial Officer of the Company. He brings with him over three decades of experience in the Indian pharmaceutical sector. Over the course of his career, he has held senior leadership roles across sales and marketing functions, managing large, multi-specialty portfolios and working closely with cross-functional teams to drive

		sustained business growth and gain market share.
Directorships held in other Companies	<ol style="list-style-type: none"> 1. Shaily Engineering Plastics Limited 2. Emcure Pharmaceuticals Limited 3. Genova Biopharmaceuticals Limited 4. Noveltech Feeds Private Limited 5. Universal Nutriscience Private Limited 	Nil
Chairmanship/ Membership in the Committees of the Boards of Companies in which he is Director	<p>Chairmanship:</p> <ol style="list-style-type: none"> 1. Shaily Engineering Plastics Limited <ul style="list-style-type: none"> • Nomination and Remuneration Committee • Risk Management Committee 2. Emcure Pharmaceuticals Limited <ul style="list-style-type: none"> • Risk Management Committee 3. Genova Biopharmaceuticals Limited <ul style="list-style-type: none"> • Audit Committee <p>Membership:</p> <ol style="list-style-type: none"> 1. Shaily Engineering Plastics Limited <ul style="list-style-type: none"> • Audit Committee • Stakeholders' Relationship Committee 	<p>Chairmanship: Nil</p> <p>Membership: Nil</p>

	<p>2. Genova Biopharmaceuticals Limited</p> <ul style="list-style-type: none"> • Corporate Social Responsibility Committee • Nomination and Remuneration Committee <p>3. Noveltech Feeds Private Limited</p> <ul style="list-style-type: none"> • Audit Committee • Corporate Social Responsibility Committee 	
No. of Board Meetings attended during FY 2025-26 (till the date of Notice)	5 out of 5	Nil
No. of Shares held in the Company and % of Paid-up Share Capital	Nil	Nil
Terms and conditions of appointment or re-appointment	To be re-appointed as an Independent Director for second term of 5 (five) consecutive years, not liable to retire by rotation.	Appointment as Director (Executive) of the Company, liable to retire by rotation. He is also being appointed as Whole-time Director of the Company for period of three (3) years with effect from February 03, 2026.
Details of remuneration sought to be paid	During his tenure as an Independent Director, Dr. Shailesh Ayyangar he shall be eligible to receive sitting fees and commission as per the provisions of the Act and the Remuneration Policy of the Company.	As included in the resolution set out in Item No. 3.
Details of remuneration last drawn	Sitting Fees of Rs. 2,10,000/- and Commission of Rs. 45,00,000/- were paid to Dr. Ayyangar for FY 2024-25	Rs. 54,69,606/- <i>(During FY 2025-26, prior to appointment on the Board of the Company)</i>

**ROUTE MAP FOR THE VENUE OF
THE EXTRA-ORDINARY GENERAL MEETING (NO. 02/2025-26)**



Route map shown from Bhumkar Chowk Bridge to the venue of EGM

Venue of the Extra-Ordinary General Meeting:

Zuventus Healthcare Limited, Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune – 411 057, Maharashtra.

Prominent Landmark: Infosys Limited, Hinjawadi Phase-II, Pune

ATTENDANCE SLIP

ZUVENTUS HEALTHCARE LIMITED

CIN: U85320PN2002PLC018324

Registered Office: Plot No. P-1 & P-2, IT - BT Park, Phase II, M.I.D.C,

Hinjawadi, Pune - 411057, Maharashtra, India

Phone: 020-35070033, 35070000, E-mail id: zuventus.corporate@zuventus.com

Website: www.zuventus.com

EXTRA-ORDINARY GENERAL MEETING (NO. 02/2025-26) –

TUESDAY, MARCH 10, 2026

Name of the Beneficial Owner: _____
Registered Folio No.: _____
No. of Shares held: _____

I / We certify that I/ We am/are a member/proxy for the member of the Company.

I/We hereby record my / our presence at Extra-Ordinary General Meeting (No. 02/2025-26) of the Company held on Tuesday, March 10, 2026 at the Registered Office of the Company situated at Plot No. P-1 & P, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra at 10.30 a.m. (IST).

.....
Name of attending Member/Proxy

.....
Member's/Proxy's Signature
(To be signed at the time of handing over this slip)

Note:

1. Sign this attendance slip and hand it over at the Extra-Ordinary General Meeting venue.
2. Body Corporate(s), whether a Company or not, who are Members, may attend through their authorized representatives appointed under Section 113 of the Companies Act, 2013. A copy of authorization should be deposited with the Company.
3. In case of shares held in Demat/Electronic Form, the signature of the Beneficial Owner is liable for verification with the record furnished to the Company by NSDL/CDSL.
4. The map to reach the EGM venue is given overleaf.

ZUVENTUS HEALTHCARE LIMITED

Form No. MGT-11

Proxy form

*[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of
the Companies (Management and Administration) Rules, 2014]*

CIN: U85320PN2002PLC018324

Name of the Company: Zuventus Healthcare Limited

Registered office: Plot No. P-1 & P-2, IT - BT Park, Phase II, M.I.D.C,
Hinjawadi, Pune - 411 057, Maharashtra

Name of the member (s):

Registered address:

E-mail Id:

Folio No/ Client Id:

I/We, being the member (s) of shares of the above named Company, hereby appoint

1. Name:
Address:
E-mail Id:
Signature:....., or failing him

2. Name:
Address:
E-mail Id:
Signature:....., or failing him

3. Name:
Address:
E-mail Id:
Signature:.....

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Extra-Ordinary General Meeting (No. 02/2025-26) of the Company, to be held on Tuesday, March 10, 2026 at 10.30 a.m. (IST) at Plot No. P-1 & P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.	Particulars	For	Against	Abstain
1.	Re-appointment of Dr. Shailesh Ayyangar (DIN: 00268076) as an Independent Director of the Company			
2.	Appointment of Mr. Salil Kumar Pandey (DIN: 11521644) as a Director of the Company			
3.	Appointment of Mr. Salil Kumar Pandey (DIN: 11521644) as a Whole-time Director of the Company			

(Please indicate the manner in which you want the proxy to vote on your behalf by putting a tick mark against your choice in respect of each resolution)

Signed this day of 2026

Signature of shareholder

Affix Revenue Stamp

Signature of proxy holder(s)